PipelineReview. Business Intellegence Center

Antibodies

1 June 2014

FibroGen Announces Results of Phase 2 Study of FG-3019 Indicating Positive Activity Against Pancreatic Cancer

1 June 2014

AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meetin

1 June 2014

Amgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer

1 June 2014

Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study

1 June 2014

Genmab Announces Ofatumumab Development Plans in RRMS and NMO

30 May 2014

AbbVie Presents Results from Study of Investigational Compound in Patients with Glioblastoma at the American Society of Clinical Oncology’s 50th Annual Meeting

30 May 2014

Genzyme’s Lemtrada Resubmission Accepted for Review by FDA

28 May 2014

Xencor Initiates Phase 1 Study of XmAb7195 for Asthma

28 May 2014

Dyax Corp. Announces Dosing of First Subject in Phase 1b Trial of DX-2930 in Patients with Hereditary Angioedema

28 May 2014

Ganymed’s IMAB362 Shows Strong Evidence of Single-Agent Activity in Phase IIa Trial in Gastroesophageal Cancer

27 May 2014

BioInvent sells back its rights to drug development candidate ADC-1013 to Alligator Bioscience AB

24 May 2014

FDA Approves First-Line Use of Vectibix® (Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer

23 May 2014

CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia

23 May 2014

Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARKⓇ for Treatment of Giant Cell Tumor of Bone

21 May 2014

Immunomedics Reports Results With IMMU-132 in Patients With Pancreatic Cancer

21 May 2014

The New England Journal Of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment

21 May 2014

FDA Approves Takeda’s Entyvio(tm) (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

20 May 2014

GSK and Genmab announce top-line results from a pivotal head-to-head study of ofatumumab in combination with chemotherapy vs. rituximab in combination with chemotherapy for the treatment of relapsed or refractory diffuse large b-cell lymphoma

19 May 2014

Immunomedics Reports Updated Results With 90Y-Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer

19 May 2014

Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma

19 May 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

19 May 2014

FibroGen Announces Phase 2 Data Supporting Longer-Term Safety and Efficacy Profile of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis

16 May 2014

Diabetes-obesity new drug (LAPS-GLP-1/GCG) enters into a global phase 1

15 May 2014

NovelMed Announces Positive Data on its Humanized Antibody in Two Models of Osteoarthritis (OA)

15 May 2014

Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference

15 May 2014

Novasep’s EUR 4 million plant extension for commercial ADC payload manufacturing now commissioned

15 May 2014

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma

15 May 2014

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b Non-Small Cell Lung Cancer Trials

15 May 2014

Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study

15 May 2014

In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
Aflibercept (Eylea) Biosimilars Pipeline Review
Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA
Report Package: Claudin 18.2-Targeted Immunotherapeutics
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
Adalimumab (Humira) Biosimilars Pipeline Review
PD-1 Agonists Pipeline Review
Ranibizumab (Lucentis) Biosimilars Pipeline Review
Claudin 6: A target opportunity to develop effector-enhanced drug modalities